GIST sensitive: personalising the adjuvant choice

Speaker: Heikki Joensuu

H.Joensuu explains the molecular science behind practical benefits obtained with adjuvant imatinib in sensitive GIST and offers a detailed analysis of results of various clinical trials in this setting. He also indicates how to best select patients for this treatment option.

Discussion Points

  • Can you dig into the molecular science that is behind some practical benefits?
  • Can you feature results of adjuvant clinical studies in GIST?
  • What is your preferred algorithm for personalising adjuvant treatment of GIST?